Convince

We would like to thank all patients for their participation in the CONVINCE Trial.

The Trial results have been analysed and have recently been presented at the European Stroke Organisation Conference in Switzerland. They have also been published in The Lancet medical journal. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00968-1/fulltext

The purpose of the CONVINCE Trial was to investigate whether an anti-inflammatory medication called colchicine used with standard treatment leads to fewer strokes and heart attacks, compared to standard treatment alone.

In the primary analysis, colchicine reduced the number of strokes and heart attacks compared to routine care, but the difference did not reach the scientific level for statistical significance, so it could not be concluded with a high degree of certainty that these results were caused by colchicine treatment. The possibility remains that they may be due to chance.

In secondary analyses, there were other strong suggestions that colchicine may be beneficial to prevent strokes and heart attacks.

The CONVINCE trial has demonstrated that further large studies of colchicine treatment are needed and these trials are being planned in several countries worldwide. If proven, colchicine will be a valuable treatment to protect stroke survivors against future strokes and heart attacks.